Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7207572 | 0.98 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL24801938 | 0.92 | SOS1 (0.48) | SOS1SOS2 | |
| Trifluoroacetic Acid SCHEMBL31579834 | 0.88 | SOS1 (0.35) | SOS1SOS2 | |
| SCHEMBL18828765 | 0.83 | SOS1 (0.43) | SOS1SOS2 | |
| SCHEMBL18706072 | 0.82 | SOS1 (0.39) | SOS1SOS2 | |
| SCHEMBL31276193 | 0.80 | SOS1 (0.38) | SOS1SOS2 | |
| SCHEMBL617658 | 0.79 | SOS1 (0.39) | SOS1SOS2 | |
| SCHEMBL13383209 | 0.78 | CYP3A4 (0.32) | SOS1SOS2 | |
| SCHEMBL799357 | 0.76 | SOS1 (0.35) | SOS1SOS2 | |
| SCHEMBL10263734 | 0.76 | SOS1 (0.35) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024243485-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-4050006-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-31 | — | — | EP | disclosed |
| CN-114945562-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021080359-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-29 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | SOS1 4536/4885SOS2 4527/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | SOS1 4536/4885SOS2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.